Wednesday, October 24, 2012 6:34:21 PM
By Mark Lawson | More Articles
October 24, 2012
The European Medicines Agency on Wednesday affirmed that it is bringing an infringement procedure against Roche (RHHBY.OB), claiming that the company did not properly check out some 80,000 reports of issues received from U.S. patients and doctors relating to 19 of the firm’s drugs, including the top performers Herceptin and Avastin. Roche could be penalized by as much as 5 percent of its yearly revenues if found guilty.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) go over the cliff on word that on Wednesday the FDA rejected the firm’s new drug application for treprostinil, which is an oral treatment for high blood pressure. The agency said that it is uncertain as to whether another evaluation would help reverse its decision, but did indicate that if the company elects to conduct a further trial, it should consider a fixed dose design and more frequent dosing.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
The drug maker XOMA (NASDAQ:XOMA) will to offer 13.33 million shares of common stock at $3 per share, and intends to use the proceeds for ongoing development and testing of its diabetes treatments gevokizumab and XMet platform, along with other corporate purposes.
Discovery Laboratories (NASDAQ:DSCO) shares sharply dip but rebound on the news that the commercial intro of its Surfaxin liquid medication to treat Infant Respiratory Distress Syndrome will probably be postponed until the second quarter of next year. The launch had previously been planned to occur by the end of the current year.
Recent RHHBY News
- Roche's Cancer Injection Tecentriq SC Gets European Commission Approval • Dow Jones News • 01/16/2024 06:49:00 AM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche • Dow Jones News • 12/29/2023 10:07:00 PM
- Roche's Xolair Granted FDA Priority Review • Dow Jones News • 12/19/2023 03:27:00 PM
- Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment • Dow Jones News • 12/11/2023 03:31:00 PM
- Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment • Dow Jones News • 12/08/2023 05:56:00 PM
- Roche's Inavolisib Breast Cancer Drug Gets Positive Results • Dow Jones News • 12/08/2023 05:38:00 PM
- Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials • Dow Jones News • 12/06/2023 10:14:00 AM
- Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study • Dow Jones News • 12/05/2023 06:54:00 AM
- Trending: Roche to Buy Carmot Therapeutics in Deal Worth Up to $3.1 Billion • Dow Jones News • 12/04/2023 03:12:00 PM
- Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update • Dow Jones News • 12/04/2023 11:34:00 AM
- Alaska Air Acquires Hawaiian Holdings, Spotify Cuts 1,500 Jobs, Uber’s S&P 500 Entry, and More • IH Market News • 12/04/2023 10:55:07 AM
- Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Billion • Dow Jones News • 12/04/2023 06:47:00 AM
- Roche's Genentech, Nvidia Team Up to Accelerate Drug Discovery With AI • Dow Jones News • 11/21/2023 04:06:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2023 10:14:35 PM
- Roche Says Late-Stage Muscular Dystrophy Trial Didn't Meet Main Goal • Dow Jones News • 10/31/2023 06:26:00 AM
- Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment • Dow Jones News • 10/27/2023 05:40:00 AM
- Trending: Roche to Buy Telavant From Roivant and Pfizer • Dow Jones News • 10/23/2023 07:41:00 PM
- Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update • Dow Jones News • 10/23/2023 08:16:00 AM
- Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal • Dow Jones News • 10/23/2023 05:50:00 AM
- Roche Shares Fall on Lower Sales Due to Currency Hit • Dow Jones News • 10/19/2023 09:55:00 AM
- Roche Backs Guidance After Sales Fall • Dow Jones News • 10/19/2023 05:48:00 AM
- Roche Lung Cancer Drug Reduced Risk of Recurrence, Death in Late-Stage Trial • Dow Jones News • 10/18/2023 06:14:00 AM
- Roche's Elecsys IL-6 Test Approved for Diagnosis of Neonatal Sepsis • Dow Jones News • 10/18/2023 05:54:00 AM
- AbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple Myeloma • Dow Jones News • 09/29/2023 12:15:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM